We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics (GPCR) rose 1.5% after a report suggested that the obesity drug maker could be a top takeover target ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S. Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully ...

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to ...

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate aleniglipron, and after closing a public offering that raised about US$748 ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Chief Scientific Officer, Fiona Marshall and Chief Executive Officer, Malcolm Weir, will present views of a high resolution X-ray crystal structure of the Corticotropin Releasing Factor (CRF-1) ...